Archives of Clinical Microbiology

  • ISSN: 1989-8436
  • Journal h-index: 22
  • Journal CiteScore: 7.55
  • Journal Impact Factor: 6.38
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • The Global Impact Factor (GIF)
  • Open Archive Initiative
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Google Scholar
  • Scimago Journal Ranking
  • Secret Search Engine Labs
  • ResearchGate
Share This Page

Drugs side effects in pregnant women infected with HIV referred to Imam Khomeini Hospital, voluntary counseling and Testing Center Tehran, Iran 2009-2013

EuroSciCon Conference on Virology and Infectious Diseases
April 22-23, 2019 | Athens, Greece

Zahra Bayat Jozani, Zohreh Rostam Afshar, Lila Taj and Minoo Mohraz

Iranian Research Center of HIV/AIDS-Tehran University of Medical Sciences, Iran

Posters & Accepted Abstracts: Arch Clin Microbiol


Objective: To obtain enough information about the prevalence of the ARV side effects in pregnant women infected with HIV and their infants and also evaluate drug efficacy in decreasing HIV infection in their children.

Method: This descriptive study was based on information of 40 pregnant women infected with HIV files at voluntary and counseling center, Imam Khomeini Hospital, Tehran, Iran during 2009 -2013. In this study, we evaluated epidemiologic, demographic, clinical, laboratory data and drugs side effects.

Results: The most commonly used drug group was AZT/3TC/EFV. About 75.5% of patients received mother to child prevention and 27.5% received ARV Antiretroviral therapy treatment. 5% anemia, 2.5% rash and 2.5% pre rupture of membranes were reported and no preeclampsia or gestational diabetes was reported in patients’ files. Only one abortion (2.5%) was occurred in late first trimester. Except rash, other adverse effects were solely reported in ARV treatment group. All neonates had normal Apgar score. Fetal defects were not reported at birth.

Conclusion: In this evaluation, safety of ARV in pregnancy period and at birth was observed especially in the group received prevention of mother to child transmission (PMTCT). So we advise ARV treatment or PMTCT in pregnancy period.

Biography :